文献速递眼底病与葡萄膜炎

非感染性葡萄膜炎患者从原研英夫利西单抗换用生物类似药后炎症复发率研究

Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis.
PubMed 文献 · Am J Ophthalmol · 2020-08-12

PURPOSE: To describe the frequency of ocular flares in patients with noninfectious uveitis who were switched from the originator infliximab to a biosimilar infliximab. DESIGN: Retrospective case series.…

要点

  • 多数复发(66.7%)发生在换药后90天内。
  • 复发患者可能通过增加生物类似药剂量达到静息。

核心结论

  • 换用生物类似药infliximab-abda后,非感染性葡萄膜炎患者的复发频率高于使用原研英夫利西单抗时。

研究设计与样本

  • 回顾性病例系列,纳入17例因非医疗原因从原研英夫利西单抗换用infliximab-abda的非感染性葡萄膜炎患者,排除任一药物随访不足3个月者。

主要发现

  • 换药后6例复发患者中4例(66.7%)在90天内复发。
  • 原研药期间仅1例复发患者换药后出现单次复发。

临床怎么用

  • 换用生物类似药infliximab-abda后应密切观察患者,尤其在前90天内。
  • 换药后出现复发者可尝试增加生物类似药剂量以达到静息。

局限性

  • 回顾性研究,样本量小(17例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the frequency of ocular flares in patients with noninfectious uveitis who were switched from the originator infliximab to a biosimilar infliximab. DESIGN: Retrospective case series. METHODS: All patients with noninfectious uveitis who were switched from the originator infliximab to biosimilar infliximab-abda for nonmedical reasons were reviewed. Patients were excluded if they had less than 3 months of follow-up on either drug. Data included patient demographics, infliximab dosage information, additional immunosuppression medications, and numbers of and times to flares. The main study outcome was frequency of flares, defined as new or worsening inflammatory activity on examination or imaging. RESULTS: A total of 17 patients met the inclusion criteria. There were no statistical differences between the duration of follow-up while on the originator and the duration while on the biosimilar infliximab (12.0 vs. 10.1 months, respectively; P = .307). Patients experienced more flares per person-years after switching to infliximab-abda (.92), than on the originator infliximab (0.19; P = .028). Four of the 6 patients (66.7%) who experienced flare after switching to infliximab-abda did so within 90 days. Only 1 patient had flares while on originator infliximab went on to develop a single flare on infliximab-abda. The final normalized dosage for patients who flared and remained on infliximab-abda (1.301 mg/kg/week) was higher than that for those who did not flare (1.186 mg/kg/week) but was not statistically significant (P = .417). CONCLUSIONS: Patients who were switched to biosimilar infliximab-abda experience more flares than when previously treated with the originator infliximab. Providers should closely observe patients who switch to biosimilar infliximab, especially within the first 90 days. Patients who do have flares after switching may achieve quiescence with increased biosimilar dosage.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Deaner JD, Srivastava SK, Hajj-Ali RA, et al. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis. Am J Ophthalmol. 2020. PMID: 32795432. doi:10.1016/j.ajo.2020.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。